LONDON—One of Roche Holding AG's most promising new drugs—for women with an aggressive form of breast cancer—has been rejected by the panel that advises the U.K. health service on the grounds that it is too expensive.. The decision by the National Institute for Health and Care Excellence, known as NICE, reflects growing pressure on drug companies from health authorities in Europe and U.S. insurers over pricing.. Ireland's...
  